• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Background Aldosterone synthase controls the synthesis of aldosterone and has been a
pharmacologic target for the treatment of hypertension for several decades. Selective …

BIOTRONIK's First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter
vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularisation of …

In Japan, a super-aged society, deaths from atherosclerotic cardiovascular disease
(ASCVD), especially cardiac diseases including coronary artery disease (CAD) such as …

Background Patients with peripheral artery disease who have undergone lower-extremity
revascularization are at high risk for major adverse limb and cardiovascular events. The …

Peripheral artery disease (PAD) is a prevalent condition that confers substantial morbidity
and mortality and remains underdiagnosed as well as undertreated in the overall …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Diabetic foot ulcers (DFUs) have become one of the important causes of mortality and
morbidity in patients with diabetes, and they are also a common cause of hospitalization …

Background: The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor
evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the …